Molecular breast imaging (MBI) is increasingly recognized as a critical tool for breast cancer diagnosis, especially in dense-breasted women, where traditional mammography often fails. Using only a small amount of radioactive tracer and a special gamma camera to identify cancerous cells, MBI provides clearer imaging results for certain patient groups. Being non-invasive, relatively less expensive compared to an MRI, and effective at an early stage of detection, these are few of the important aspects contributing toward the growth of the market.
Factors such as increasing number of breast cancer cases, improvement in health care infrastructure, and rising awareness towards early detection is driving the growth of MBI market globally. Other innovations in the field of nuclear medicine imaging and improving access to MBI systems across hospitals and diagnostic centers further support the penetration of the market. MBI is fast becoming the method of choice for breast imaging as screening guidelines expand and more women seek personalized and accurate diagnostics.
The market is projected to grow at a compound annual growth rate (CAGR) of 4.4% from 2025 to 2035, increasing from USD 637 Million in 2025 to USD 970.24 Million by 2035.
Metric Overview
| Metric | Value |
|---|---|
| Market Size (2025) | USD 637 Million |
| Market Value (2035) | USD 970.24 Million |
| CAGR (2025 to 2035) | 4.4% |
North America is a dominator in the molecular breast imaging market with its well-established healthcare infra along with a robust presence of diagnostic imaging companies and favourable reimbursement policies. The country that continues to lead the market is the United States due to a rise in breast cancer prevalence and national awareness campaigns backing proactive screenings.
Europe shows healthy growth in the MBI market which is further supported by increasing adoption of new imaging techniques and government initiatives in breast cancer screening. With such countries as Germany, France, and Sweden, MBI is now coming into clinical practice alongside mammography for women having dense breast tissue.
Asia-Pacific is set to realize maximum growth as compared to other regional markets due to constant and increasing investments in health technologies, expansion of diagnostic infrastructures, and improving awareness about breast cancer screening. Therefore, demand for cost-effective imaging modalities is increasing in China, India, and Japan, making MBI become a potential method for better cancer detection in this part of the world.
High Equipment Costs and Limited Accessibility
An important hurdle posed by MBI capital costs constitutes a large interest to smaller healthcare facilities and institutions in limited-resource settings. Therefore, it remains a hindrance to the MBI's wider uptake in developing regions with limited budgets for health care.
Radiation Exposure Concerns
MBI results in better imaging of dense breast tissues, it involves the injection of radioactive tracers into patients. The fear of the radiation dose, especially with repeated screenings, can dampen patient and provider acceptance of MBI over other modalities.
Advancements in Imaging Technology
The improvement in detective sensitivity and image resolution acts as a gradual conversion factor of MCI in diagnosis. The recent advancement has made MBI more tempting in early detection of cancer in dense tissues poorly performed by conventional mammography.
Growing Emphasis on Early Detection
The rising awareness of the importance of early detection of breast cancer has created demand for more precise diagnostic tools. MBI, through its unique ability to detect some tumours otherwise occult on mammograms, has therefore emerged as a very valuable adjunct imaging technique.
| Market Shift | 2020 to 2024 Trends |
|---|---|
| Technology Adoption | Limited to specialized centers |
| Regulatory Approvals | Slow and region-specific |
| Cost Considerations | High equipment and operational costs |
| Clinical Guidelines | MBI as adjunct in specific cases |
| Patient Awareness | Limited awareness among patients |
| Research and Development | Focus on improving image quality |
| Market Shift | 2025 to 2035 Projections |
|---|---|
| Technology Adoption | Broader adoption across various healthcare settings |
| Regulatory Approvals | Streamlined processes facilitating faster approvals |
| Cost Considerations | Technological advancements leading to cost reductions |
| Clinical Guidelines | Potential inclusion in standard screening protocols |
| Patient Awareness | Increased education leading to higher acceptance and demand |
| Research and Development | Emphasis on reducing radiation dose and enhancing patient comfort |
The USA market is attributing its growth to the extremely advanced medical imaging technology and high awareness level on screening for breast cancer. Also present supportive reimbursement policies by the critical medical device manufacturers and their strong presence are also contributing significantly to the increasing MBI adoption in hospitals, diagnostic centers, and specialty clinics.
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 4.6% |
The increase in the demand for advanced diagnostic tools such as MBI can also be attributed to government investment into health and strong national screening programs in the United Kingdom. The strengthening of academic collaborations and public-private partnerships also help the advancement of further innovation in imaging technologies and greater accuracy in diagnosis, particularly for the high-risk patient groups in early detection efforts.
| Country | CAGR (2025 to 2035) |
|---|---|
| United Kingdom | 4.2% |
The harmonized cancer screening policies in the European Union, the aging population, and the increasing interest for accurate diagnostic processes would be promising for these markets. Major countries such as Germany, France, and Italy are spending enormously on next-generation imaging solutions and making the European Union a strong market for MBI technology in early breast cancer detection.
| Region | CAGR (2025 to 2035) |
|---|---|
| European Union | 4.3% |
The rapid aging of the population and the growing cancer screening programs have been propelling the MBI market in Japan. Innovations in technology from domestic manufacturers, along with the government's support for healthcare, bring forth the early diagnosis. Furthermore, cultural belief in regular health check-ups leads to an increase in the use of enhanced new imaging devices, like MBI, in cities.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 4.4% |
In South Korea, the molecular breast imaging market is expanding due to increasing government healthcare initiatives, growing public awareness about breast cancer screening, and the need for high-sensitivity diagnostic tools. Adoption is also supported by investments in nuclear medicine infrastructure and collaboration between hospitals and medical imaging companies.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 4.5% |
| By Modality | Market Share (2025) |
|---|---|
| Dual Head Camera | 63.5% |
In the MBI industry, dual-head gamma cameras are expected to be the market leader in 2025, holding 63.5% of the market share. These systems have better resolution and sensitivity than a single-head and therefore can detect even the smallest lesions better in women with dense breast parenchyma. With dual detectors that acquire simultaneous images from opposing views, they reduce patient scanning time and ensure comfort during screening and diagnosis.
With improved reliability of diagnosis, they are particularly useful for detecting cancers that may not be seen on conventional mammography. The globally rising incidence of breast cancer, coupled with a focus on early detection and personal imaging, has made hospitals and diagnostic centers embrace dual-head MBI systems for accurate and reliable screening even more.
| By Application | Market Share (2025) |
|---|---|
| Diagnosis | 58.7% |
The segment of diagnosis applications is anticipated to rule the MBI market in terms of shares amounting to 58.7% by the year 2025. MBI assumes significance as an added adjunct diagnostic tool for the patients with inconclusive mammograms or results from ultrasound examinations, as it provided better lesion detectability, especially with dense breast tissues. It's unlike the traditional imaging modality that is not functional but rather gives imaging via radiotracer uptakes for better visualization of cancer activity.
Its specificity is high enough to reduce false positives and unnecessary biopsies. As clinicians are further moving toward imaging for treatment planning, especially high-risk patients, the application of MBI as a diagnostic tool is also becoming more popular. The expanding coverage for reimbursement and continued research on the development of new radiotracers will only make it a stronger candidate in the landscape of diagnostic imaging.
The growing incidence of breast cancer around the world combined with the increasing demand for advanced diagnostics techniques has aided the molecular breast imaging (MBI) market in realizing healthy growth. Enhanced sensitivity for detecting tumours is offered by MBI, especially in women with dense breast tissues, for whom mammography has been less effective.
Advancements in technology, dual-head gamma cameras, and improved radiotracers presently propel the adoption of the MBI system. The region with the highest growth currently in this domain is North America, thanks to the well-developed healthcare infrastructure, extensive R&D activities, and a greater amount of dollars within the health care system.
Market Share Analysis by Key Players
| Company Name | Estimated Market Share (%) |
|---|---|
| GE Healthcare | 20-25% |
| Siemens Healthineers | 15-20% |
| Hologic, Inc. | 10-15% |
| Koninklijke Philips N.V. | 8-12% |
| Canon Medical Systems Corporation | 5-10% |
| Others | 20-30% |
| Company Name | Key Offerings/Activities (with Year) |
|---|---|
| GE Healthcare | Offers the Discovery NM750b MBI system, featuring high-resolution detectors for improved lesion detection. |
| Siemens Healthineers | Provides the Symbia Intevo MBI system, integrating advanced imaging technologie s for precise diagnostics. |
| Hologic, Inc. | Develops the Selenia Dimensions system with molecular imaging capabilities, enhancin g breast cancer detection. |
| Koninklijke Philips N.V. | Introduced the BrightView XCT system, combining molecular imaging with CT for com prehensive breast imaging. |
| Canon Medical Systems Corporation | Offers the Celesteion PET/CT system, facilitating molecular imaging for oncology applications, including breast cancer. |
Key Market Insights
GE Healthcare (20-25%)
With its Discovery NM750b system, noted for high-resolution detectors and advanced imaging capability in aiding early detection of breast cancer, GE Healthcare leads the MBI market.
Siemens Healthineers (15-20%)
Siemens Healthineers has a market share of 15-20%. For example, its Symbia Intevo ensures enhanced patient outcomes through accurate diagnostics by the combination of advanced technology and molecular imaging.
Hologic Inc. (10-15%)
This Selenia Dimensions system from Hologic is based on features of molecular imaging that will facilitate enhancements of breast cancer detection, especially in women with dense breast tissue.
Koninklijke Philips N.V. (8-12%)
The BrightView XCT of Philips integrates molecular imaging with CT to offer a comprehensive breast imaging solution that enhances the accuracy of diagnosis.
Canon Medical Systems Corporation (5-10%)
The Celesteion PET/CT of Canon performs molecular imaging for oncology applications, including breast cancer, thus providing comprehensive support for precise diagnosis and treatment planning.
Other Key Players (20-30% Combined)
The overall market size for Molecular Breast Imaging market was USD 637 Million in 2025.
The Molecular Breast Imaging market is expected to reach USD 970.24 Million in 2035.
The demand for molecular breast imaging will rise due to increasing breast cancer cases, need for early and accurate diagnostics, advancements in dual-head camera technology, and growing adoption in specialized care centers.
The top 5 countries which drives the development of Molecular Breast Imaging market are USA, European Union, Japan, South Korea and UK
Dual Head Camera Systems demand supplier to command significant share over the assessment period.
Explore Diagnostic Devices Insights
Molecular Breast Imaging Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
